Insulin-like growth factor 1 (IGF-1) influences cell proliferation and survival. In the extracellular environment, IGF-1 circulates bound to proteins (IGF-binding proteins; IGFBP), some of which have physiological effects that seem independent of IGF-1, including the brain (for example, IGFBP-3). We completed a systematic review of the association between dementia and IGF-1 and IGFBP-3, and a cross-sectional and longitudinal study designed to investigate if lower plasma concentration of these proteins increased the risk of prevalent and incident dementia. A total of 3967 men aged 71-89 years joined the study, of whom 535 (13.5%) showed evidence of prevalent cognitive impairment. The plasma concentrations of IGF-1 and IGFBP-3 were similar for men with and without cognitive impairment. The 3432 men free of cognitive impairment were then followed for up to 13 years. During this time 571 (16.6%) developed dementia. The plasma concentration of IGF-1 had no association with incident dementia. The doubling of the plasma concentration of IGFBP-3 decreased the hazard ratio of dementia by 23% (95% confidence interval = 5-37%). The results were not affected by age, body mass index and history of smoking, diabetes, hypertension, coronary heart disease or stroke. If these findings are confirmed by others, the plasma concentration of IGFBP-3 could be used to improve the accuracy of predictive models of dementia and as a potential new factor to assist in the development of prevention and treatment strategies.
INTRODUCTION
Insulin-like growth factor 1 (IGF-1) is a hormone that is structurally similar to the pro-insulin peptide and mediates, among other things, the growth-promoting effects of the human growth hormone. 1 Most IGF-1 circulates bound to other proteins, which are known as IGF-binding proteins (IGFBPs). Six IGFBPs have been described to date (IGFBP-1 to -6-see reference for detailed review of their physiological functions), 2 with IGFBP-3 recently attracting attention because of its various physiological effects that seem largely independent of IGF-1. 3 For example, currently available evidence suggests that IGFBP-3 could contribute to mediate cell proliferation, death and survival. 3 In later life, lower concentration of IGFBP-3 has been associated with higher mortality rates, 4 while IGFBP-3 overexpression has been observed in some cancers 2 and in the brains of people who have died with Alzheimer's disease. 5 Given these findings, it is not surprising that several groups have investigated the association between dementia and IGF-1 and IGFBP-3.
Seven cross-sectional studies have examined the relationship between dementia and IGF-1. 6 Taken together, their results suggest that people with dementia (n = 616) have lower circulating IGF-1 than healthy controls (n = 726). However, there was evidence of marked study heterogeneity, suboptimal methodological quality and publication bias (Supplementary eTables 1 and 2; Supplementary eFigure 1). Similar methodological problems beset the six studies that compared IGFBP-3 in people with (n = 510) and without dementia (n = 493) (Supplementary eTables 1 and 2; Supplementary eFigure 1). Hence, existing evidence suggests that the nature of the association between dementia and IGF-1 and IGFBP-3 remains uncertain.
There are limited data investigating the longitudinal association between IGF-1 or IGFBP-3 and incident dementia. The Caerphilly study used blood samples from 745/2512 (29.7%) men who subsequently underwent cognitive assessment over a 20-year period. 7 They found no obvious association between baseline concentration of IGF-1 or IGFBP-3 and incident dementia or cognitive impairment, 7 although selective sampling and differential loss to follow-up created uncertainty about the validity and generalisability of the findings.
The Health In Men Study has been collecting longitudinal data from a community-representative sample of older men since 1996. During the 2001-2004 assessment, about 4000 participants donated a blood sample and have since been followed continually using the Western Australian Data Linkage System (WADLS), 8 thereby circumventing concerns about differential loss to followup. We used the Health In Men Study to investigate the crosssectional and longitudinal association between the plasma concentration of IGF-1 and IGFBP-3 and cognitive impairment or dementia. On the basis of our systematic review of the topic (Supplementary Material), we hypothesised that participants with dementia would have lower plasma concentration of both IGF-1 and IGFBP-3, and that lower baseline concentration of IGF-1 and IGFBP-3 would be associated with greater risk of incident dementia over 10 years than high concentrations. 4 
MATERIALS AND METHODS

Study design, setting and participants
The Health In Men Study is a cohort study of a community-representative sample of older men living in the Perth metropolitan region of Western Australia, Australia. Details about the recruitment of participants have been described elsewhere. 9 Briefly, 4243 men donated a blood sample during the 2001-2004 wave of assessments, and valid assays for IGF-1 and IGFBP-3 were available for 3967 participants (93.5%). The flow of participants in this study is summarised in Supplementary eFigure 2. Their age ranged from 71 to 89 years and together they formed the sample for this investigation. They were followed until they received the diagnosis of dementia, died or the 30 June 2015, whichever occurred first. Participants provided written informed consent and all study procedures were approved by the Human Research Ethics Committee of the University of Western Australia.
Outcomes: cognitive impairment and dementia
During the 2001-2004 assessment we examined participants with the Mini-Mental State Examination (MMSE) and considered that those with a total score of 23 or less had cognitive impairment. 10 In addition, we retrieved data from WADLS to determine whether a diagnosis of dementia had been recorded between 1 January 1980 and 30 June 2015. WADLS incorporates information for all health contacts in Western Australia, including emergency departments, elective and non-elective admissions, mental health outpatient services, community aged care services, as well as cancer and death registries. 8 Each occasion of service leads to the recording of the date and the relevant primary and up to 20 secondary diagnoses that are coded according to the International Classification of Diseases (ICD). The following ICD-9 and ICD-10 codes indicate the presence of dementia: 290, 294.1, 294.2, 331.0, 331.1, 331.2 and 331.82; and F00, F01, F02, F03, G30, G31.0, G31.1 and G31.83. We made no attempt to examine individual types of dementia because 'unspecified dementia' was the most frequently recorded diagnosis. The diagnoses recorded in WADLS rely on all clinical data available at the time, including information obtained from the next-of-kin, general practitioners, medical notes and investigations. WADLS does not record the sources of information used to reach a diagnosis, only that a diagnosis was established.
In this study, we considered that prevalent cognitive impairment was present if the MMSE score was ⩽ 23 or if a diagnosis of dementia had been recorded in WADLS before the 2001-2004 assessment. For the longitudinal study, we excluded from the sample men with prevalent cognitive impairment (as described above) and used WADLS to establish the onset of dementia during follow-up. For the longitudinal study, the baseline date was the date of the assessment of each participant during 2001-2004 wave.
Exposures: IGF-1 and IGFBP-3
We collected blood samples from participants between 0800 and 1030 hours during the 2001-2004 visit. Plasma was separated immediately after collection and stored at − 80C until assayed. We used commercial reagent kits of single lot numbers to measure IGF-1 and IGFBP-3 (Diagnostics Systems Laboratories-supplied by Beckman Coulter, Gladesville, NSW, Australia). A Grifols Triturus ELISA processor was used to automate the assays (Vital Diagnostics, Castle Hill, NSW, Australia). Coefficients of variation were 12.2% and 8.6% for IGF-1 concentrations of 117 and 216 ng ml − 1 , respectively, and 16.8% and 4.4% for IGFBP-3 concentrations of 540 and 4300 ng ml − 1 , respectively.
Other study measures
At the 2001-2004 assessment participants provided information about their age (in years), date of birth, educational achievement (completed high school vs incomplete high school-recorded at the time of recruitment) and smoking (never, past or current). We used a self-report questionnaire to establish the presence of diabetes, hypertension, coronary heart disease and stroke: 'Have you ever been told that you have diabetes (yes/no), hypertension (yes/no), angina (yes/no), heart attack (yes/no), heart bypass surgery (yes/no), heart balloon angioplasty (yes/no), stroke (yes/no)'. We considered that men had coronary heart disease if they answered 'yes' any of the questions about angina, heart attack, heart bypass surgery or heart balloon angioplasty. We used a standardised scale to measure the weight (in kg-light clothing and no shoes) and the height (in cm) of participants, and calculated their body mass index (BMI) using the formula: BMI = weight/(height/100) 2 . This survey did not have access to information about history of dementia in the family of participants.
Statistical analyses
We managed and analysed the data with the statistical package Stata 14.2 (StataCorp, College Station, TX, USA). We used descriptive statistics to summarise study measures as counts, proportions, range, mean and s.d. of the mean, and compared men with and without cognitive impairment at study entry using Pearson's χ 2 -statistic and t-tests. In the case of IGF-1 and IGFBP-3 concentrations, the analyses were further adjusted for the confounding effect of age, educational attainment, and history of coronary heart disease and stroke using analysis of variance.
We subsequently excluded from the analyses men with prevalent cognitive impairment and calculated the risk of incident dementia using a range of approaches. First, we calculated the doubling of IGF-1 and IGFBP-3 by dividing the natural log of these measures by the natural log of 2, and then used Cox regression to estimate the crude and adjusted hazard ratio (HR) of dementia (analyses adjusted for age and history of smoking, diabetes and stroke) resulting from the doubling of IGF-1 and IGFBP-3. Second, we grouped participants into quintiles of IGF-1 and IGFBP-3, and estimated the HR of dementia for each quintile using the lowest quintile as the reference. Again, the analyses were later adjusted for age and history of smoking, diabetes and stroke. Finally, we calculated the probability of dementia according to the plasma concentration of IGF-1 and IGFBP-3 using the 'predict' subcommand of Stata following a logistic regression analysis adjusted for age and history of smoking, diabetes and stroke-the findings were plotted in graphic form using the 'twoway qfitci' command of Stata.
We also completed a series of post hoc analyses designed to ensure that the possible association between dementia and IGF-1 and IGFBP-3 concentrations was not due to differential mortality or to the inclusion of false negative cases of dementia in the cohort. We used competing risk regression to address the former (risk ratio expressed as sub-HR (SHR) and the respective 95% confidence interval (CI)) and dealt with the latter by repeating the analyses after excluding men who had developed dementia or had died during the initial 2 years of follow-up. The codes used for the statistical analyses are available from the corresponding author.
The results of all analyses reported in this manuscript were two-tailed, and alpha was set at 5%.
Sample size
We estimated that the study would require a sample size of 3153 participants to declare as significant a HR of 0.8 associated with an event probability of 20% (power 80%). The study had access to 3432 men for the longitudinal study.
RESULTS
The mean ± s.d. age of the 3967 participants was 77.0 ± 3.6 years. Of these, 535 (13.5%) showed evidence of cognitive impairment (only 15 men with diagnosis of dementia in WADLS did not have MMSE ⩽ 23). Table 1 summarises the sociodemographic, lifestyle and clinical characteristics of men with and without cognitive impairment. Men with cognitive impairment were, on average, nearly 1 year older (77.8 ± 3.8 vs 76.9 ± 3.6 years; t = 5.21, Po 0.001). In addition, a lower proportion of them had completed high school, and the prevalence of coronary heart disease and stroke was higher amongst those with cognitive impairment. The plasma concentration of IGF-1 was similar among men with and without cognitive impairment. The plasma concentration of IGFBP-3 was lower among men with than without cognitive impairment, but the difference between the groups disappeared once we took into account in the analysis the effects of age, education and history of coronary heart disease and stroke (Table 1) .
We then followed the 3432 men without cognitive impairment for 9.2 ± 3.4 years (range: 0.1-13.6 years). During this time, 571 (16.6%) developed dementia and 1230 (35.8%) died free of dementia. The doubling in the plasma concentration of IGF-1 at study entry was associated with a HR of dementia of 1.03 (95% CI = 0.90-1.18; HR = 1.04, 95% CI = 0.91-1.18 after adjustment for age, smoking group, history of diabetes, coronary heart disease and stroke, and BMI at baseline). In contrast, doubling of the plasma concentration of IGFBP-3 decreased the HR of dementia during follow-up (HR = 0.73, 95% CI = 0.59-0.89; HR = 0.77, 95% CI = 0.63-0.95 after adjustment for age, smoking group, history of diabetes, coronary heart disease and stroke, and BMI at baseline). Men in the lowest quintile of IGFBP-3 concentration had 47% (95% CI = 1-64%) greater risk of developing dementia than their counterparts in the highest quintile of IGFBP-3 concentration (41%, 95% CI = 8-84% after adjustment for age, smoking group, history of diabetes, coronary heart disease and stroke, and BMI at baseline). We did not attempt to use multiple imputation for these multivariate analyses because there were missing data for 10 participants only.
We subsequently grouped participants into quintiles of IGF-1 and IGFBP-3 concentrations and re-ran the Cox regression analyses. The results of these analyses are summarised in Table 2 . The plasma concentrations of IGFBP-3 for each quintile were, in order, 603-3010, 3020-3560, 3570-4020, 4030-4530 and 4540-7600 ng ml − 1 . Figure 1 shows the adjusted probability of incident dementia according to the plasma concentration of IGF-1 and IGFBP-3.
Post hoc analyses
We re-ran our analyses using death as a competing risk for dementia. The doubling of IGFBP-3 was associated with a SHR of dementia of 0.72 (95% CI = 0.59-0.88-analyses adjusted for age, smoking group, history of diabetes, coronary heart disease and stroke, and BMI at baseline). Similarly, the SHR of dementia associated with IGFBP-3 quintiles was, in order, 0.84 (95% CI = 0.66-1.07), 0.89 (95% CI = 0.70-1.13), 0.68 (95% CI = 0.52-0.88) and 0.69 (95% CI = 0.53-0.90). In all, 23 men developed dementia and 127 died during the initial 2 years of follow-up. After excluding these participants from the analyses, we found that the adjusted SHR of dementia associated with the doubling of IGFBP-3 remained largely unchanged at 0.72 (95% CI = 0.59-0.89). The respective adjusted SHR of dementia associated with IGFBP-3 quintiles for this subsample was 0.88 (95% CI = 0.69-1.13), 0.90 b P = 0.292 after the analyses were adjusted for age (in years), educational attainment and past history of coronary heart disease or stroke. (Educational attainment was included in these analyses because it was associated with both cognitive impairment and IGFBP-3.) Abbreviations: 95% CI, 95% confidence interval of the hazard ratio; HR, hazard ratio; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor-binding protein 3. a Analyses adjusted for age, smoking group, history of diabetes, coronary heart disease and stroke, and body mass index. (Education was not included in the adjusted analyses because it did not affect the risk estimate of dementia; P = 0.349).
(95% CI = 0.70-1.15), 0.68 (95% CI = 0.52-0.89) and 0.70 (95% CI = 0.54-0.92). These associations did not change after we excluded from the analyses participants who had developed dementia or had died within the first 4 years of follow-up-this happened despite progressive loss of power (data not shown). Finally, we re-ran our analyses after excluding participants with the lowest and highest 1% of values if IGFBP-3. The crude HR of dementia associated with the doubling of IGFBP-3 concentration was 0.65 (95% CI = 0.51-0.83) and the adjusted HR 0.69 (95% CI = 0.54-0.88-adjusted for age, smoking group, history of diabetes, coronary heart disease and stroke, and BMI at baseline).
DISCUSSION
The results of this study showed that the plasma concentration of IGF-1 is not associated with cognitive impairment either crosssectionally or longitudinally. In contrast, we found that the concentration of IGFBP-3 is lower among older men with cognitive impairment (although the association was no longer significant after adjustment for other study measures) and is inversely associated with incident dementia. Doubling of the plasma concentration of IGFBP-3 decreased the risk of incident dementia by about 25%. Men in the lowest quintile of IGFBP-3 concentration had, on average, 40% greater risk of developing dementia over a 9-year period than their counterparts in the highest quintile of concentrations.
This project has the merit of having used a community-derived sample of older men recruited through random sampling of the Western Australian Electoral Roll (voting in Australia is mandatory for all adults aged 18 years or over), 9 although those who were frail were less likely to be available for assessment. 11 Hence, our results apply to a group of older men living in the community who were free of significant functional impairments at the time of enrolment-this would have excluded people with moderate to severe dementia from our cross-sectional analyses, which would have biased the results towards the null hypothesis. Such bias would not have affected the longitudinal study (people with prevalent cognitive impairment were excluded), and this may explain why the inverse association between IGFBP-3 and dementia risk could only be confirmed for incident cases. We are also mindful of the fact that we recruited a sample of men aged 70 years or over, and that the associations that we observed may not necessarily apply to women or younger men. For example, hypertension in midlife, but not in later life, is strongly associated with the development of dementia. 12 It is conceivable that the risk of dementia associated with exposure to IGF-1 and IGFBP-3 in early and late life may differ, but a prolonged longitudinal study starting in midlife would be required to clarify such a possibility. Finally, we acknowledge we were unable to contrast the predictive value of IGFBP-3 concentration with wellestablished risk factors for dementia, such as the ApoE4. We are not aware of any data suggesting that ApoE4 could mediate some of the effects of IGFBP-3, but this is an issue that will require the attention of future studies.
We used the MMSE and WADLS to establish the presence of cognitive impairment in our cross-sectional study. The MMSE is a valid and widely used measure to establish the presence of cognitive impairment, 10 which we enriched by using WADLS (2.8% of the men with prevalent cognitive impairment had MMSE ⩾ 24). The longitudinal arm of the study benefited from negligible loss to follow-up, as all health contacts and deaths are recorded by WADLS and the migratory movement of older Western Australians is minimal. 13 We are also confident that our findings on incident dementia were not due by contamination of the sample with prevalent cases, as the results remained unchanged in our sensitivity analyses. We concede, however, that the diagnosis of dementia retrieved from WADLS was not based on a structured clinical assessment, but on information retrieved from hospital and aged care community services. This creates some uncertainty regarding the accuracy of the diagnosis of dementia in the study. Existing evidence indicates that WADLS has good specificity for the diagnosis of dementia (negligible number of false positive cases), but its sensitivity (particularly for mild cases) may be suboptimal. 14 The longitudinal design of the study may have contributed to mitigate the impact of such a bias on the calculation of incidence rates (as cases are eventually recorded over time as the disease progresses), and, indeed, the incidence rates that we observed are consistent with those reported by others using different methodologies. 15 This suggests that the approach we used to calculate risk estimates is likely to have produced robust results.
We should also consider the possibility of misclassification and bias associated with low IGFBP-3. Lower plasma concentration of IGFBP-3 has been associated with increased morbidity and mortality. 2, 3 Thus, people with low concentration of IGFBP-3 may more promptly and frequently come to medical attention, which would then increase the opportunity for the diagnosis of dementia to be made earlier. This could potentially bias this association, in which case the real risk of dementia associated with low IGFBP-3 could be less robust than our data suggest. Finally, we acknowledge that residual confounding and random error could conceivably explain some of our findings, as could confounding Figure 1 . Probability of incident dementia (black line) and respective 95% confidence interval (grey line) among older men during a mean follow-up period of 9 years (range: 0.1-13.6) according to their baseline serum concentration of insulin-like growth factor 1 (IGF-1; left panel) and IGF-binding protein 3 (IGFBP-3; right panel). Probability estimates were derived from logistic regression and the analysis was adjusted for age, history of smoking, diabetes and stroke, and body mass index.
due to unmeasured factors (for example, nutritional status, alcohol use and IGF-2). For example, IGF-1 and IGF-2, together with the acid-labile subunit, form stable complexes with circulating IGFBP-3, 3 so that low concentration of IGFBP-3 may imply low concentration of IGF-2 when the concentration of IGF-1 remains unchanged. As information on IGF-2 was not available for this study, we could not examine its effect on cognitive outcomes.
Four of the seven cross-sectional studies currently available found that people with dementia have lower plasma concentration of IGFBP-3 than healthy controls, [16] [17] [18] two found no difference between the groups 19, 20 and one reported higher IGFBP-3 concentrations among older adults with dementia. 21 One longitudinal survey found no obvious association between IGFBP-3 and risk of dementia, although follow-up cognitive data were only available for less than half of the original sample (our study had follow-up data for all participants). 7 A recent investigation designed to clarify the role of IGFBP-3 in the brain found that IGFBP-3 null mice (mice engineered to not express IGFBP-3) display deficiencies in neuronal structure and signalling. 22 These mice also showed behavioural abnormalities suggestive of impaired working memory and visuospatial difficulties. Such findings indicate that IGFBP-3 contributes to modulate certain aspects of brain function and that IGFBP-3-deficient brains may be more vulnerable to cognitive deficits. There is also some evidence that IGFBP-3 contributes to repair damaged DNA, but inhibits cell replication and promotes cell death when there is marked genomic damage. 3 If the results of basic research could be translated to humans, one might speculate that the brains of people with low circulating IGFBP-3 may be less efficient at repairing genomic damage and that this would lead to an increase in the rate of brain cell loss and, ultimately, dementia. Future studies should seek to replicate our findings and clarify whether the association between IGFBP-3 and dementia is truly causal. Should that be the case, the plasma concentration of IGFBP-3 may prove to be a useful marker of dementia risk and, potentially, offer new insights into how to prevent and treat dementia.
In summary, we found that IGF-1 was not associated with either prevalent or incident dementia, whereas low plasma concentration of IGFBP-3 was associated with increased probability of incident dementia over a 9-year period. If these results are confirmed by others, the plasma concentration of IGFBP-3 could be used to improve the accuracy of predictive models and as a potential new factor that might assist in the prevention and treatment of dementia.
